PBAC's latest decision on Elotuzumab: Recommended with restriction (2021). Considered for Treatment of relapsed or refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone, in patients who have received at least one prior therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2020
Submissions
2
2020 → 2021
Eligible population
Patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy, treated with elotuzumab in combination with lenalidomide and dexamethasone.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
Meta-analysis
Primary endpoint
OS
Key trials
ELOQUENT-2, ENDEAVOR
Comparator
carfilzomib and dexamethasone (Cd)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis presented; ICER not applicable as cost-minimisation model used.
Submission history
Nov 2020: Recommended with restriction · Authority Required
Jul 2021: Recommended with restriction · Authority Required